Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | APEX1 | P27695 | 1/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13363152 | 0.83 | KCNH2 (0.32) | KCNH2LMNAAPEX1PMP22CYP19A1 | |
| SCHEMBL28410691 | 0.78 | KCNH2 (0.37) | KCNH2LMNAAPEX1PMP22CYP19A1 | |
| SCHEMBL21456288 | 0.78 | KCNH2 (0.31) | KCNH2LMNAAPEX1PMP22 | |
| SCHEMBL1502646 | 0.75 | CYP19A1 (0.31) | CYP19A1 | |
| SCHEMBL14994336 | 0.74 | — | — | |
| SCHEMBL6004752 | 0.73 | KCNH2 (0.31) | KCNH2 | |
| SCHEMBL190709 | 0.72 | NUDT1 (0.32) | — | |
| SCHEMBL18706496 | 0.72 | — | — | |
| SCHEMBL16792284 | 0.72 | — | — | |
| SCHEMBL574865 | 0.71 | CYP19A1 (0.32) | CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 791 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024184926-A1 | PROCESS FOR PREPARATION OF CHIRAL RUXOLITINIB AND SALTS THEREOF | AARTI PHARMALABS LIMITED (IN) | 2024-09-12 | — | — | WO | claimed |
| CN-115960121-A | Method for synthesizing 1- (3-oxa-cyclobutylcyclo-alkyl) -1H-pyrazole-4-boronic acid pinacol ester | 南通药明康德医药科技有限公司 | 2023-04-14 | — | — | CN | claimed |
| CN-114805368-A | Preparation method of ruktinib | 山东诺明康药物研究院有限公司 | 2022-07-29 | — | — | CN | claimed |
| CN-114380853-A | Preparation method of 4-pyrazole boronic acid pinacol ester | 南京焕然生物科技有限公司 | 2022-04-22 | — | — | CN | claimed |
| CN-112645878-A | N-containing compound with specific response to pressure stimulation, preparation method and application | 北京工业大学 | 2021-04-13 | — | — | CN | claimed |
| CN-112500580-A | Preparation method and application of cobalt-based metal organic framework catalyst for activating oxygen molecules | 大连理工大学 | 2021-03-16 | — | — | CN | claimed |
| CN-111943959-A | Synthetic method of JAK inhibitor | 上海再极医药科技有限公司 | 2020-11-17 | — | — | CN | claimed |
| CN-110698506-A | Synthesis method of pyrazole-4-boronic acid pinacol ester | 怀化旺达生物科技有限公司 | 2020-01-17 | — | — | CN | claimed |
| EP-4737451-A1 | NOVEL CARBOXAMIDE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Dong Wha Pharm. Co., Ltd. (KR) | 2026-05-06 | — | — | EP | disclosed |
| US-12618830-B2 | Methods, culture medias and devices for generating embryos in vitro from stem cells | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2026-05-05 | — | — | US | disclosed |
| US-20260070919-A1 | CRYSTAL FORM OF FIVE-MEMBERED AND SIX-MEMBERED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | BEIJING MAXINOVEL PHARMACEUTICALS CO LTD (CN) | 2026-03-12 | — | — | US | disclosed |
| US-20260062678-A1 | CELL REPLACEMENT THERAPY FOR PULMONARY DISEASES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2026-03-05 | — | — | US | disclosed |
| EP-4692367-A1 | SCREENING METHOD FOR COMPOUND INDUCING AUTOPHAGY | Tohoku University (JP) | 2026-02-11 | — | — | EP | disclosed |
| EP-3891149-B1 | RET INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | SUNSHINE LAKE PHARMA CO LTD (CN) | 2026-01-28 | — | — | EP | disclosed |
| US-20070281943-A1 | Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-12-06 | — | — | US | disclosed |
| EP-1846392-A2 | HETEROCYCLIC TRIAZINES AS HYPOXIC SELECTIVE PROTEIN KINASE INHIBITORS | Sentinel Oncology Limited (GB) | 2007-10-24 | — | — | EP | disclosed |
| WO-2007011809-A1 | SPIROCHROMANONE DERIVATIVES AS ACETYL COENZYME A CARBOXYLASE (ACC) INHIBITORS | MERCK & CO., INC. (US) | 2007-01-25 | — | — | WO | disclosed |
| US-20070021453-A1 | Novel spirochromanone derivatives | MERCK SHARP & DOHME LLC | 2007-01-25 | — | — | US | disclosed |
| WO-2006131835-A2 | HETEROCYCLIC TRIAZINES AS HYPOXIC SELECTIVE PROTEIN KINASE INHIBITORS | SENTINEL ONCOLOGY LIMITED (GB) | 2006-12-14 | — | — | WO | disclosed |
| US-20060111387-A1 | ARYL SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY | 2006-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021453-A1 | Novel spirochromanone derivatives | HSD17B7, CYP11B2, CYP11B1 | KCNH2 1735/4885LMNA 2178/4885APEX1 1772/4885 |
| US-20260062678-A1 | CELL REPLACEMENT THERAPY FOR PULMONARY DISEASES | WNT3A, BMP4, GSK3B | KCNH2 4764/4885LMNA 989/4885APEX1 4869/4885 |
| US-20070281943-A1 | Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases | IKZF3, IRAK2, IRAK1 | KCNH2 2626/4885LMNA 1882/4885APEX1 4250/4885 |
| US-12618830-B2 | Methods, culture medias and devices for generating embryos in vitro from stem cells | POU2F1, POU5F1, POU2F2 | KCNH2 1755/4885LMNA 2778/4885APEX1 4219/4885 |
| US-20260070919-A1 | CRYSTAL FORM OF FIVE-MEMBERED AND SIX-MEMBERED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | WEE2, WEE1, CYP7B1 | KCNH2 1518/4885LMNA 2094/4885APEX1 3353/4885 |
| US-20060111387-A1 | ARYL SUBSTITUTED IMIDAZOQUINOLINES | IL2, IFNG, IRF3 | KCNH2 4354/4885LMNA 4453/4885APEX1 3759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.